- Home
- BTMD vs BDTX Comparison
BTMD vs BDTX Comparison
Compare BTMD & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- BDTX
- Stock Information
- Founded
- BTMD 2012
- BDTX 2014
- Country
- BTMD United States
- BDTX United States
- Employees
- BTMD N/A
- BDTX N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTMD Health Care
- BDTX Health Care
- Exchange
- BTMD Nasdaq
- BDTX Nasdaq
- Market Cap
- BTMD 127.8M
- BDTX 132.5M
- IPO Year
- BTMD N/A
- BDTX 2020
- Fundamental
- Price
- BTMD $4.02
- BDTX $3.13
- Analyst Decision
- BTMD Strong Buy
- BDTX Strong Buy
- Analyst Count
- BTMD 1
- BDTX 6
- Target Price
- BTMD $8.00
- BDTX $14.83
- AVG Volume (30 Days)
- BTMD 119.6K
- BDTX 1.3M
- Earning Date
- BTMD 08-07-2025
- BDTX 08-05-2025
- Dividend Yield
- BTMD N/A
- BDTX N/A
- EPS Growth
- BTMD 201.68
- BDTX N/A
- EPS
- BTMD 0.60
- BDTX 0.09
- Revenue
- BTMD $199,379,000.00
- BDTX $70,000,000.00
- Revenue This Year
- BTMD $5.87
- BDTX N/A
- Revenue Next Year
- BTMD $8.59
- BDTX N/A
- P/E Ratio
- BTMD $6.75
- BDTX $35.76
- Revenue Growth
- BTMD 6.44
- BDTX N/A
- 52 Week Low
- BTMD $3.04
- BDTX $1.20
- 52 Week High
- BTMD $8.35
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- BTMD 49.75
- BDTX 71.97
- Support Level
- BTMD $3.92
- BDTX $2.43
- Resistance Level
- BTMD $4.25
- BDTX $3.31
- Average True Range (ATR)
- BTMD 0.21
- BDTX 0.18
- MACD
- BTMD -0.02
- BDTX 0.05
- Stochastic Oscillator
- BTMD 22.73
- BDTX 80.85
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.